The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has delivered a positive opinion Biogen’s adalimumab biosimilar, SB5 (also known as Imraldi), referencing Humira.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has delivered a positive opinion on Biogen’s adalimumab biosimilar, SB5 (also known as Imraldi), referencing Humira. CHMP’s opinion will now be reviewed by the European Commission, which is expected to grant a marketing authorization for the drug in the European Union.
CHMP’s positive opinion is based on preclinical and clinical data comparing the biosimilar to its reference product. The clinical data include results of a phase 1 study in healthy volunteers that demonstrated pharmacokinetic (PK) equivalence between Humira and a phase 3, randomized, double-blind, multicenter study in which the biosimilar demonstrated equivalent efficacy and comparable safety and immunogenicity profiles to the reference product in patients with rheumatoid arthritis. The phase 3 study met its primary endpoint of producing, by week 24, a response of ACR20 (or the American College of Rheumatology 20% improvement in tender and swollen joint counts; patient assessments of pain, global disease activity, and physical function; physician global assessment of disease activity; and acute phase reactant).
SB5 is the third anti—tumor necrosis factor (anti–TNF) biosimilar candidate submitted to the EMA by Samsung Bioepis, a joint effort between Biogen and Samsung BioLogics. Alpna Seth, PhD, senior vice president and global head of the biosimilars business unit at Biogen, said, “This portfolio expansion is in line with our mission to increase access to biologics that have transformed the treatment of chronic autoimmune conditions like rheumatoid arthritis. Being able to provide this range of anti–TNF treatment alternatives bolsters our leadership position and underscores our commitment to expanding physician choice while supporting the sustainability of healthcare systems.”
In its official statement, Biogen estimates that the European market for anti—TNF drugs accounts for the equivalent of $9 billion in healthcare costs. Of that total cost, Humira accounts for $4 billion. While market analysts expect the reference adalimumab to remain the top-selling drug by 2022, the introduction of such biosimilar products as SB5, Amgen’s adalimumab biosimilar (known as Amjevita) that was granted its own positive opinion in January, or any of the 3 additional adalimumab biosimilar candidates currently under consideration at the EMA could exert considerable pressure on AbbVie to offer its reference product to European health systems at a more competitive price.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Sintilimab, Bevacizumab Biosimilar, HAIC Improves Survival in Patients With Unresectable HCC
April 14th 2024Positive results of sintilimab, IBI305, and hepatic arterial infusion chemotherapy (HAIC) treatment showed shrinking tumors and previously converting inoperable hepatocellular carcinoma (HCC) to resectable HCC with manageable adverse effects.